Skip to contentP
Petros Pharmaceuticals, Inc.
P
PTPIPetros Pharmaceuticals, Inc. Q2 2026 · 10-Q
Revenue—
Net Income-$955.63K-$955.63KN/M vs Q2 2025 EPS Diluted-$0.30-$0.30N/M vs Q2 2025 Operating Income-$988,501N/M Operating Cash Flowderived-$863,855N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Petros Pharmaceuticals, Inc. · CIK 1815903 · Engraved from SEC EDGAR
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end